Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 3
1970 5
1971 2
1973 3
1974 5
1975 3
1976 2
1977 5
1978 5
1979 1
1980 2
1981 6
1982 4
1983 1
1984 5
1985 4
1986 8
1987 10
1988 8
1989 19
1990 16
1991 13
1992 11
1993 19
1994 20
1995 21
1996 17
1997 23
1998 26
1999 20
2000 18
2001 19
2002 13
2003 18
2004 25
2005 25
2006 27
2007 35
2008 20
2009 13
2010 26
2011 21
2012 26
2013 38
2014 28
2015 24
2016 23
2017 28
2018 21
2019 25
2020 23
2021 27
2022 25
2023 15
2024 16
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

806 results

Results by year

Filters applied: . Clear all
Page 1
Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity: A randomized crossover trial.
Algera JP, Demir D, Törnblom H, Nybacka S, Simrén M, Störsrud S. Algera JP, et al. Clin Nutr. 2022 Dec;41(12):2792-2800. doi: 10.1016/j.clnu.2022.11.001. Epub 2022 Nov 4. Clin Nutr. 2022. PMID: 36384081 Free article. Clinical Trial.
At baseline, severity of GI symptoms and gut microbial fermentation were assessed (every 15 min, 4 h) during the Lactulose Nutrient Challenge Test (LNCT). Clinical response and FODMAP sensitivity were defined by reduction after low FODMAP period, and increase after moderat …
At baseline, severity of GI symptoms and gut microbial fermentation were assessed (every 15 min, 4 h) during the Lactulose Nutrient C …
Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).
de Wit K, Schaapman JJ, Nevens F, Verbeek J, Coenen S, Cuperus FJC, Kramer M, Tjwa ETTL, Mostafavi N, Dijkgraaf MGW, van Delden OM, Beuers UHW, Coenraad MJ, Takkenberg RB. de Wit K, et al. BMJ Open Gastroenterol. 2020 Dec;7(1):e000531. doi: 10.1136/bmjgast-2020-000531. BMJ Open Gastroenterol. 2020. PMID: 33372103 Free PMC article. Clinical Trial.
METHODS AND ANALYSIS: The Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a TIPS (PEARL) trial, is a multicentre randomised, double blind, placebo controlled trial. Patients undergoi …
METHODS AND ANALYSIS: The Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver ci …
Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.
Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Rahimi RS, et al. JAMA Intern Med. 2014 Nov;174(11):1727-33. doi: 10.1001/jamainternmed.2014.4746. JAMA Intern Med. 2014. PMID: 25243839 Free PMC article. Clinical Trial.
OBJECTIVE: To compare polyethylene glycol 3350-electrolyte solution (PEG) and lactulose treatments in patients with cirrhosis admitted to the hospital for HE. We hypothesized that rapid catharsis of the gut using PEG may resolve HE more effectively than lactulose. D …
OBJECTIVE: To compare polyethylene glycol 3350-electrolyte solution (PEG) and lactulose treatments in patients with cirrhosis admitte …
L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, Sonika U, Dalal A. Jain A, et al. Hepatology. 2022 May;75(5):1194-1203. doi: 10.1002/hep.32255. Epub 2021 Dec 21. Hepatology. 2022. PMID: 34822189 Clinical Trial.
APPROACH AND RESULTS: In a double-blind randomized placebo-controlled trial, 140 patients were randomized to a combination of LOLA, lactulose, and rifaximin (n = 70) or placebo, lactulose, and rifaximin (n = 70). LOLA was given as continuous intravenous infusion at …
APPROACH AND RESULTS: In a double-blind randomized placebo-controlled trial, 140 patients were randomized to a combination of LOLA, lactu …
Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
Sanyal AJ, Kowdley KV, Reau NS, Pyrsopoulos NT, Allen C, Heimanson Z, Bajaj JS. Sanyal AJ, et al. Hepatol Commun. 2024 May 10;8(6):e0436. doi: 10.1097/HC9.0000000000000436. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38727685 Free PMC article. Clinical Trial.
METHODS: Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months in a phase 3 randomized, double-blind trial and a phase 4 open-label trial was conducted. RESULTS AND CONCLUSION: Rifaximin plu …
METHODS: Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone …
A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. Sharma BC, et al. Am J Gastroenterol. 2013 Sep;108(9):1458-63. doi: 10.1038/ajg.2013.219. Epub 2013 Jul 23. Am J Gastroenterol. 2013. PMID: 23877348 Clinical Trial.
Drugs used in the treatment of HE are primarily directed at the reduction of the blood ammonia levels. Rifaximin and lactulose have shown to be effective in HE. We evaluated the efficacy and safety of rifaximin plus lactulose vs. lactulose alone for treatment …
Drugs used in the treatment of HE are primarily directed at the reduction of the blood ammonia levels. Rifaximin and lactulose have s …
Rifaximin treatment in hepatic encephalopathy.
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Bass NM, et al. N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893. N Engl J Med. 2010. PMID: 20335583 Free article. Clinical Trial.
More than 90% of patients received concomitant lactulose therapy. The incidence of adverse events reported during the study was similar in the two groups, as was the incidence of serious adverse events. ...
More than 90% of patients received concomitant lactulose therapy. The incidence of adverse events reported during the study was simil …
Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient-reported outcomes: The Mi-Kristal trial.
Tapper EB, Ospina E, Salim N, Chen X, Nikirk S. Tapper EB, et al. Hepatology. 2023 Oct 1;78(4):1159-1167. doi: 10.1097/HEP.0000000000000408. Epub 2023 Apr 18. Hepatology. 2023. PMID: 37066820 Free PMC article. Clinical Trial.
HE is a major driver of poor PROs. Many clinicians initiate lactulose therapy to address poor PROs. PRO-triggered therapy, however, has not been studied till date. ...Lactulose users reported more good sleep (92% vs. 52%, p = 0.001) and lower activity impairment (3. …
HE is a major driver of poor PROs. Many clinicians initiate lactulose therapy to address poor PROs. PRO-triggered therapy, however, h …
Clinical study of probiotics combined with lactulose for minimal hepatic encephalopathy treatment.
Shi J, Li F. Shi J, et al. Eur J Gastroenterol Hepatol. 2023 Jul 1;35(7):777-781. doi: 10.1097/MEG.0000000000002567. Epub 2023 May 3. Eur J Gastroenterol Hepatol. 2023. PMID: 37161982 Clinical Trial.
OBJECTIVE: This study aimed to investigate the clinical effect of probiotics combined with lactulose for minimal hepatic encephalopathy (MHE) treatment. METHODS: A total of 88 patients with MHE were randomly divided into the control ( n = 44) and combined groups ( n = 44). …
OBJECTIVE: This study aimed to investigate the clinical effect of probiotics combined with lactulose for minimal hepatic encephalopat …
Comparative effectiveness of lactulose and sennosides for the prevention of peritoneal dialysis-related peritonitis: an open-label, randomized, active-controlled trial.
Noppakun K, Narongchai T, Chaiwarith R, Wongsawad U, Vongsanim S, Ruengorn C, Nochaiwong S. Noppakun K, et al. Ann Med. 2021 Dec;53(1):365-374. doi: 10.1080/07853890.2021.1889023. Ann Med. 2021. PMID: 33596746 Free PMC article. Clinical Trial.
Nevertheless, the secondary outcome was significantly higher in the lactulose group (HR, 2.77 [95% CI, 1.20-6.41]; p = .010). The incidence of adverse events was not substantially different between the two groups; however, diarrhoea was more frequent in the lactulose …
Nevertheless, the secondary outcome was significantly higher in the lactulose group (HR, 2.77 [95% CI, 1.20-6.41]; p = .010). The inc …
806 results